Matthew Biegler
Stock Analyst at Oppenheimer
(2.18)
# 2,831
Out of 5,180 analysts
91
Total ratings
35%
Success rate
-0.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $38.30 | +30.55% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $772.64 | +11.95% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $9.95 | +40.70% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $14.91 | +221.93% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $23.87 | +88.52% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $12.67 | +18.39% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $8.95 | +145.81% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.50 | +80.65% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.39 | +475.54% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.70 | +48.94% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.44 | +268.85% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $17.84 | +796.86% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $10.60 | +324.53% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $139.37 | -17.49% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $33.32 | +59.06% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.34 | +754.70% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $6.15 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.67 | +82.53% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $10.69 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.20 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $21.44 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.11 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.33 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $38.30
Upside: +30.55%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $772.64
Upside: +11.95%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $9.95
Upside: +40.70%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $14.91
Upside: +221.93%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $23.87
Upside: +88.52%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $12.67
Upside: +18.39%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $8.95
Upside: +145.81%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.50
Upside: +80.65%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.39
Upside: +475.54%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.70
Upside: +48.94%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.44
Upside: +268.85%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $17.84
Upside: +796.86%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $10.60
Upside: +324.53%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $139.37
Upside: -17.49%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $33.32
Upside: +59.06%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.34
Upside: +754.70%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $6.15
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.67
Upside: +82.53%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $10.69
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.20
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $21.44
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.11
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.33
Upside: -